We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NVST Stock Up on Q1 Earnings and Revenue Beat, Margins Crash
Read MoreHide Full Article
Envista Holdings Corporation (NVST - Free Report) reported first-quarter 2025 adjusted earnings per share (EPS) of 24 cents, down 7.7% year over year. The bottom line surpassed the Zacks Consensus Estimate by 20%.
The adjustments include non-cash charges related to the amortization of acquisition-related and other intangible assets, restructuring costs and asset impairments, among others.
The company’s GAAP EPS was 10 cents compared with 14 cents in the prior-year period.
Following the announcement, shares of NVST climbed 4% last Friday.
NVST’s Q1 Revenues
Revenues totaled $616.9 million, down 1.1% year over year. However, the metric topped the Zacks Consensus Estimate by 1.5%. (See the Zacks Earnings Calendar to stay ahead of market-making news.)
Segmental Details of Q1 Revenues
In the first quarter, Specialty Products & Technologies’ revenues totaled $400.3 million, down 2.1% year over year.
Revenues from the Equipment & Consumables segment increased 0.8% year over year to $216.6 million.
NVST’s Operational Update
The gross profit in the reported quarter fell 5.7% year over year to $336 million. The gross margin contracted 267 basis points (bps) to 54.5% due to a 5.1% rise in cost of sales.
Selling, general and administrative expenses declined 4.6% year over year to $271.7 million. Research and development expenses rose 8.6% to $25.3 million.
The operating profit of $39 million fell 18.9% year over year. The operating margin contracted 139 bps to 6.3%.
NVST’s Financial Update
Envista ended the first quarter of 2025 with cash and cash equivalents of $1.08 billion compared with $1.07 billion at the end of the fourth quarter of 2024. Long-term debt amounted to $1.30 billion compared with $1.28 billion in the fourth quarter of 2024.
Year to date, net cash provided by operating activities amounted to $0.3 million compared with $40.3 million a year ago.
2025 Guidance
Envista reaffirmed its 2025 guidance.
It expects core sales growth to be 1-3% and adjusted EBITDA margins to be approximately 14%. The Zacks Consensus Estimate for 2025 revenues is pegged at $2.53 billion, suggesting a 0.8% increase from the year-ago reported figure.
Envista Holdings Corporation Price, Consensus and EPS Surprise
Adjusted EPS is anticipated to be in the band of $0.95-$1.05. The Zacks Consensus Estimate is pegged at $0.97.
Our Take on NVST
Envista closed the first quarter of 2025 with better-than-expected results, with earnings and revenues beating their respective estimates. In the quarter, the company experienced growth in its consumables, premium implants, and orthodontics (outside China) businesses. Additionally, Spark delivered another strong quarter of growth.
However, the Specialty Products & Technologies segment posted a sales decline, impacted by two significant dynamics outside the normal business drivers — a larger impact from the change in Spark revenue deferral and a decline in orthodontic China volumes. The declining gross as well as operating profit, along with the contraction of both margins during the quarter, is discouraging.
AngioDynamics, currently sporting a Zacks Rank #1 (Strong Buy), reported third-quarter fiscal 2025 adjusted EPS of 3 cents, which beat the Zacks Consensus Estimate of a loss of 13 cents. You can see the complete list of today’s Zacks #1 Rank stocks here.
Revenues of $72 million beat the Zacks Consensus Estimate by 2%. ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 composite’s 10.5%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 70.9%.
Veeva Systems, sporting a Zacks Rank #1 at present, posted fourth-quarter fiscal 2025 adjusted EPS of $1.75, which exceeded the Zacks Consensus Estimate by 10.1%. Revenues of $720.9 million surpassed the Zacks Consensus Estimate by 3.2%.
VEEV has an estimated long-term earnings growth rate of 26.6% compared with the industry’s 20.8%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.9%.
Masimo, currently sporting a Zacks Rank #1, reported fourth-quarter 2024 adjusted EPS of $1.80, which surpassed the Zacks Consensus Estimate by 20.8%. Revenues of $600.7 million topped the Zacks Consensus Estimate by 0.8%.
MASI has an estimated earnings yield of 3.5% for fiscal 2025 compared with the industry’s 3.6%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.4%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
NVST Stock Up on Q1 Earnings and Revenue Beat, Margins Crash
Envista Holdings Corporation (NVST - Free Report) reported first-quarter 2025 adjusted earnings per share (EPS) of 24 cents, down 7.7% year over year. The bottom line surpassed the Zacks Consensus Estimate by 20%.
The adjustments include non-cash charges related to the amortization of acquisition-related and other intangible assets, restructuring costs and asset impairments, among others.
The company’s GAAP EPS was 10 cents compared with 14 cents in the prior-year period.
Following the announcement, shares of NVST climbed 4% last Friday.
NVST’s Q1 Revenues
Revenues totaled $616.9 million, down 1.1% year over year. However, the metric topped the Zacks Consensus Estimate by 1.5%. (See the Zacks Earnings Calendar to stay ahead of market-making news.)
Segmental Details of Q1 Revenues
In the first quarter, Specialty Products & Technologies’ revenues totaled $400.3 million, down 2.1% year over year.
Revenues from the Equipment & Consumables segment increased 0.8% year over year to $216.6 million.
NVST’s Operational Update
The gross profit in the reported quarter fell 5.7% year over year to $336 million. The gross margin contracted 267 basis points (bps) to 54.5% due to a 5.1% rise in cost of sales.
Selling, general and administrative expenses declined 4.6% year over year to $271.7 million. Research and development expenses rose 8.6% to $25.3 million.
The operating profit of $39 million fell 18.9% year over year. The operating margin contracted 139 bps to 6.3%.
NVST’s Financial Update
Envista ended the first quarter of 2025 with cash and cash equivalents of $1.08 billion compared with $1.07 billion at the end of the fourth quarter of 2024. Long-term debt amounted to $1.30 billion compared with $1.28 billion in the fourth quarter of 2024.
Year to date, net cash provided by operating activities amounted to $0.3 million compared with $40.3 million a year ago.
2025 Guidance
Envista reaffirmed its 2025 guidance.
It expects core sales growth to be 1-3% and adjusted EBITDA margins to be approximately 14%. The Zacks Consensus Estimate for 2025 revenues is pegged at $2.53 billion, suggesting a 0.8% increase from the year-ago reported figure.
Envista Holdings Corporation Price, Consensus and EPS Surprise
Envista Holdings Corporation price-consensus-eps-surprise-chart | Envista Holdings Corporation Quote
Adjusted EPS is anticipated to be in the band of $0.95-$1.05. The Zacks Consensus Estimate is pegged at $0.97.
Our Take on NVST
Envista closed the first quarter of 2025 with better-than-expected results, with earnings and revenues beating their respective estimates. In the quarter, the company experienced growth in its consumables, premium implants, and orthodontics (outside China) businesses. Additionally, Spark delivered another strong quarter of growth.
However, the Specialty Products & Technologies segment posted a sales decline, impacted by two significant dynamics outside the normal business drivers — a larger impact from the change in Spark revenue deferral and a decline in orthodontic China volumes. The declining gross as well as operating profit, along with the contraction of both margins during the quarter, is discouraging.
Zacks Rank and Key Picks
Envista currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are AngioDynamics (ANGO - Free Report) , Veeva Systems (VEEV - Free Report) and Masimo (MASI - Free Report) .
AngioDynamics, currently sporting a Zacks Rank #1 (Strong Buy), reported third-quarter fiscal 2025 adjusted EPS of 3 cents, which beat the Zacks Consensus Estimate of a loss of 13 cents. You can see the complete list of today’s Zacks #1 Rank stocks here.
Revenues of $72 million beat the Zacks Consensus Estimate by 2%. ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 composite’s 10.5%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 70.9%.
Veeva Systems, sporting a Zacks Rank #1 at present, posted fourth-quarter fiscal 2025 adjusted EPS of $1.75, which exceeded the Zacks Consensus Estimate by 10.1%. Revenues of $720.9 million surpassed the Zacks Consensus Estimate by 3.2%.
VEEV has an estimated long-term earnings growth rate of 26.6% compared with the industry’s 20.8%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.9%.
Masimo, currently sporting a Zacks Rank #1, reported fourth-quarter 2024 adjusted EPS of $1.80, which surpassed the Zacks Consensus Estimate by 20.8%. Revenues of $600.7 million topped the Zacks Consensus Estimate by 0.8%.
MASI has an estimated earnings yield of 3.5% for fiscal 2025 compared with the industry’s 3.6%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.4%.